Screening for bipolar disorders in patients with alcohol or substance use disorders: Performance of the Mood Disorder Questionnaire  by van Zaane, Jan et al.
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Background:  Screening  properties  of  the  Mood  Disorder  Questionnaire  (MDQ)  to  detect  bipolar  disorder
(BD) in  patients  with  substance  use  disorders  are  unknown.
Methods:  403 treatment  seeking  patients  with  a substance  use  disorder  completed  the MDQ  and  subse-
quently  111  MDQ  positives  and  59 MDQ  negatives  were  assessed  with  the  Structured  Clinical  Interview
for  DSM-IV  to diagnose  BD.  In addition,  given  the  overlap  with  BD  symptoms,  the  presence  of  borderline
personality  disorder  (BPD),  antisocial  personality  disorder  (APD)  and  attention  deﬁcit/hyperactivity  dis-
order (ADHD),  were  assessed  using  the Diagnostic  Interview  Schedule  and  the  Structured  Interview  for
DSM-IV  Personality.
Results: Of  the  170 patients  with  a SCID  interview,  35  patients  (20.6%)  met  criteria  for  a lifetime  diagnosis
of  BD. Twenty-three  patients  (62.8%)  with  BD  had  a  positive  MDQ  score  and  47  of the  135 patients  (34.8%)
without  BD  had  a negative  MDQ  score  resulting  in  a weighted  sensitivity  of  .43,  a weighted  speciﬁcity  ofttention deﬁcit/hyperactivity disorder .57, a  positive  predictive  value  of  .21,  a negative  predictive  value  (NPV)  of .80  and an  area  under  the curve
of .50.  The  area  under  the  curve  of  the MDQ  to detect  BPD,  APD,  ADHD  and  any  externalizing  disorder
ranged  from  .55  (APD)  to  .63  (ADHD).
Conclusions:  The  MDQ  is not  a suitable  screening  instrument  for  the  detection  of  BD  or other  externalizing
disorders  but  it could  be used  for ruling  out  the presence  of  BD  in  treatment  seeking  substance  use disorder
patients.. Introduction
Substance use disorders (SUD) frequently co-occur with other
sychiatric disorders, including bipolar disorders (BD). Population
ased epidemiological studies have shown that subjects with an
lcohol use disorder (AUD) or drug use disorder (DUD) are 5–6
imes more likely to have a history of (hypo)manic and depres-
ive episodes associated with BD than subjects without SUD (Regier
t al., 1990; Kessler et al., 1997; Kessler, 1995). Among the main
auses of the world wide Top-20 of Years of Life Lived in Disabil-
ty in 2000 of 15–44 years-olds (both sexes) AUD, BDs and DUD are
anking respectively 2nd, 5th and 16th. The frequent comorbidity of
D and SUD is, therefore, a substantial economical burden (World
ealth Organization, 2001; Murray, 1994; Murray and Lopez, 1996;
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Lopez and Murray, 1998). In many BD patients with comorbid SUD,
BD remains unrecognized because the episodic alterations in mood
and energy in patients with SUD are not recognized as symptoms
of BD. Underdiagnosis of BD is more common in BD type II (BD-II)
than in BD type I (BD-I), because episodes with manic symptoms
but without dysfunction can be difﬁcult to identify (Hirschfeld et al.,
2003a; Suppes et al., 2001).
Albanese et al. (2006) showed that 29% of a sample of 295 Cau-
casian males admitted to a substance abuse program had a form of
BD and half of them had not been previously diagnosed with BD and
consequently were not treated for it. In addition, the US National
Depressive and Manic-Depressive Association 2000 Survey of indi-
viduals with BD showed that 37% reported alcohol and substance
abuse during the time that they were not or improperly treated for
their BD, while alcohol and substance abuse dropped to 14% when
treatment was  initiated (Hirschfeld et al., 2003a).
Open access under the Elsevier OA license.In order to improve the detection of BD in a population of treat-
ment seeking SUD patients we  decided to introduce a screening
instrument: the Mood Disorder Questionnaire (MDQ). The MDQ
is a brief and easy-to-use self-report screening inventory for the
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etection of bipolar spectrum disorders (Hirschfeld et al., 2000,
003b,c; Chung et al., 2008). The original MDQ  (Hirschfeld et al.,
000) was validated in psychiatric outpatients with mainly mood
isorders and showed a sensitivity of 0.73 and a speciﬁcity of 0.90.
rom 2000 on, the MDQ  has been subject to validation in different
atient groups and settings with different prevalences of BD-I, BD-
I, and BD not otherwise speciﬁed (BD-NOS) (Chung et al., 2008). The
DQ has also been validated in the general population (Hirschfeld
t al., 2003c)  and in a forensic setting (Kemp et al., 2008). In these
tudies, the Structured Clinical Interview for DSM-III-R or DSM-IV
xis-I disorders (SCID-I/P) (Spitzer et al., 1992; First et al., 1995)
as used as the gold standard. The ﬁndings of these studies were
ather mixed. Some studies showed (very) good sensitivity and or
peciﬁcity (Chung et al., 2008; Stang et al., 2007; Twiss et al., 2008;
aratiegui et al., 2011). However, Zimmerman et al. (2009) reported
nadequate sensitivity (0.64) and reasonable speciﬁcity (0.85) in a
sychiatric outpatient sample. Therefore, in an attempt to improve
ts sensitivity, it was proposed to omit the requirement of impair-
ent based on section C of the MDQ. Indeed, this modiﬁed MDQ,
howed better sensitivity (0.75) but lower speciﬁcity (0.79) while
he positive predictive value (PPV) remained below 30% (Chung
t al., 2008; Zimmerman et al., 2009). The authors recommended
urther studies, e.g., among patients with SUD (Chung et al., 2008;
immerman et al., 2009, 2011). Recently, Villagonzalo et al. (2010)
ound that 49% of a group of 74 methadone maintenance patients
creened positive for BD using the MDQ, although only 3 clients
ad an active diagnosis of BD on their medical records. However, in
his study no standardized assessment was performed to diagnose
he presence of DSM-IV BD and, therefore, the screening qualities
f the MDQ  is still unknown in treatment seeking SUD patients.
As far as we know, this is the ﬁrst study examining the screen-
ng properties of the MDQ  using the SCID as a gold standard to
etect BD in patients with SUD, in whom a relatively high preva-
ence of BD is expected. We,  therefore, hypothesized that the MDQ
ould be a valid screen for the detection of BD in this population.
ince symptoms of substance abuse can mimic  manic symptoms
e decided to add two questions to the original MDQ  in order to
llow us to exclude substance induced BD. We  hypothesized that
dding these questions would reduce false positives and therefore
ncrease speciﬁcity (Zimmerman et al., 2004).
Furthermore, we decided to also assess the presence of bor-
erline personality disorder (BPD), antisocial personality disorder
APD) and attention deﬁcit/hyperactivity disorder (ADHD), because
hese disorders are very prevalent in patients with SUD and the
ymptoms of these disorders overlap with BD symptoms. We  thus
ypothesized that a considerable amount of patients with a posi-
ive screen would meet criteria for BPD, APD or ADHD but not for
D.
. Methods
.1. Subjects and recruitment
The study took place between August 2005 and June 2007 in two  addiction
reatment centers in Amsterdam and Alkmaar (the Netherlands). The participants
ere a series of consecutive referred new patients. A total of 403 were recruited:
8%  outpatients and 42% inpatients. Patients had to meet the following inclusion
riteria: (1) in need of (see below) and seeking treatment for AUD or SUD, (2) being
bstinent since seeking treatment (self report and clinical judgement), (3) able and
illing to participate in the study, and (4) adequate command of the Dutch language.
atients with a score of less than 23 on the Mini Mental State Examination (MMSE)
Folstein et al., 1975), indicating cognitive impairment, were excluded.
The study was approved by the Ethical Review Board of the participating centers
nd all patients provided written informed consent..2. Need of treatment
At baseline, the European Addiction Severity Index (EuropASI) (Kokkevi and
artgers, 1995) was administrated by trained professionals. This is a semi-
tructured interview measuring problem severity on a 10 point scale (0–9), includingependence 124 (2012) 235– 241
the following domains: medical condition, alcohol, drugs, family/social relations and
mental problems. Patients with scores ≥4 are in need of (additional) treatment.
2.3. Screener: Mood Disorder Questionnaire (MDQ)
The original MDQ  was translated into Dutch by two independent translators. The
resulting consensus translation was  then back translated into English by a native
English mental health professional. In a consensus meeting where attention was
paid to both semantic and conceptual equivalence, the three of them reviewed and
approved the ﬁnal version (Postma and Schulte, 2008).
The MDQ  has three sections. The ﬁrst section has 13 yes/no BD items derived
from the DSM-IV criteria (American Psychiatric Association, 1994) and from clinical
experience (section A). The MDQ  screen is regarded to be positive if seven or more
items from section A are present, if several of these items co-occur (section B) and
if  they caused moderate or serious problems (section C). Since substance use can
mimic  bipolar symptoms we added two questions to the original MDQ. First, partic-
ipants were asked whether any of the endorsed section A symptoms ever happened
during an episode with little or no substance use (section D). Second, participants
were asked whether they ever had an episode without section A symptoms in which
they felt their normal self (section E). In summary: the MDQ  classic is considered
positive if sections A, B and C are fulﬁlled, whereas the adjusted MDQ  is considered
positive if the requirements for sections A, B, C, D and E are fulﬁlled.
2.4. Diagnostic instruments
BD and SUD were assessed using the mood and substance use disorders sections
of  the SCID-I/P, Dutch version (Groenesteijn van et al., 1998). BD included BD-I,
BD-II and BD-NOS. ADHD was diagnosed with the ADHD section of the Diagnostic
Interview Schedule (DIS) (Robins et al., 1981), and BPD and APD with the borderline
and antisocial personality disorder sections of the Structured Interview for DSM-IV
Personality (SIDP-IV) (Pfohl et al., 1997).
2.5. Design
At baseline, i.e., three days after intake (T0), all patients were asked to complete
the  MDQ. At T1, i.e., after another 1–2 weeks all still abstinent patients with a pos-
itive  score on the MDQ  at T0 and a random 1:4 sample of patients with a negative
score on the MDQ  at T0 were, after they had provided written informed consent,
invited to complete the MDQ  again and the diagnostic assessments (SCID-1/P, DIS,
SIDP-IV, MMSE). These diagnostic assessments were performed by specially trained
research psychologists who were blind for the MDQ  score at T0. This assessment
(T1) was performed later in order to avoid contamination by intoxication or with-
drawal symptoms possibly still present at T0. All assessments were monitored by
psychiatrists (JvZ or BvdB).
2.6. Statistical analysis
In order to check the random procedure to select MDQ negative patients at T0
for the full assessment at T1, sociodemographic and clinical characteristics between
MDQ  negatives with and without an assessment were compared using t-tests and
Pearson’s Chi-Square tests for nominal and ordinal data. P-values below 0.05 were
considered statistically signiﬁcant.
SCID diagnoses were used as external criterion for the calculation of the sensitiv-
ity, speciﬁcity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), positive
predictive value (PPV), and negative predicted value (NPV) of the MDQ.  In order to
take into account the different proportion of MDQ  positives (111/161 = 0.689) and
MDQ  negatives (59/214 = 0.276) who were assessed with the SCID (Fig. 1), estimates
for  sensitivity and speciﬁcity were weighted according to these sampling fractions
(Whitmore et al., 1999). In order to compare the MDQ  performance using differ-
ent  external criteria and different MDQ  versions (using only section A or sections
A  plus B) in a SUD population, receiver operating curve (ROC) analyses were con-
ducted taking into account differences in sampling fractions between MDQ  screen
positives and MDQ  screen negatives. As hypomanic episodes in DSM-IV are (by deﬁ-
nition) not associated with marked impairment in social or occupational functioning
as  required for a positive MDQ  score, there might be under-detection of BD II. There-
fore, analyses were repeated without the impairment criterion (section C). Finally,
since substance use can mimic manic symptoms, all analyses were repeated taking
into account sections D and E.
3. Results
3.1. Recruitment and sample characteristics
After baseline (T0), 28 of the 403 included patients were
excluded due to inadequate scoring of the MDQ  (Fig. 1). Of the
375 remaining patients, 161 (43%) patients were MDQ  positive and
214 (57%) were MDQ  negative. All MDQ  positives (N = 161, 43%)
and a random sample of the MDQ  negatives (N = 60, 28%) were
J. van Zaane et al. / Drug and Alcohol Dependence 124 (2012) 235– 241 237
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pproached for the second assessment (T1). A total of 50 MDQ
ositives (31%) were lost to follow-up due to relapse, drop-out or
nability to be traced after discharge from the inpatient department.
he data of one MDQ  negative patient were excluded from further
nalyses due to a score of less than 23 on the MMSE  at T1. As a result,
he analyses of the operating characteristics of the MDQ included
ata of 111 of all 161 MDQ  positives (68.9%) and 59 of all 214 MDQ
egatives (27.6%). These fractions (0.689 and 0.276) were used as
eighting factors in the calculations.
Because the MDQ  is a screening instrument that is likely to be
sed early in the diagnostic process, in the primary analyses MDQ
ata at T0 were used in the comparison with the SCID at T1. In a sec-
ndary analysis we also compared MDQ  data at T1 with SCID data at
1. It should be noted, however, that the test–retest correlation of
he total sum scores of the MDQ  section A scores (all cases N = 170)
etween T0 and T1 was rather high (R = .604, p < .0001 [correlation
s signiﬁcant at the 0.01 level], R2 = .36): test–retest correlation of
he MDQ  positive cases was .455 (R2 = .21) and for MDQ  negative
ases .608 (R2 = .37).
able 1
ociodemographic characteristics versus MDQa results.
Characteristics MDQ  positives N = 161 (43%) MD
Age, mean y, (±sd) 38.45 (9.76) 41
Gender n, (%)
Male 133 (83%) 150
Female 28 (17%) 64
Education level n, (%)
≤High school 118 (73%) 142
>High  school 25 (16%) 44
unknown 18 (11%) 28
Employment status n, (%) 
Employed 27 (17%) 39
Unemployed 81 (50%) 88
Unknown 53 (33%) 87
EuropASIb, mean (±sd)
Medical state 2.32 (1.83) 2
Alcohol 3.88 (2.48) 4
Drugs  3.70 (2.71) 2
Family/social relations 3.58 (2.08) 3
Mental problems 4.62 (2.12) 4
a MDQ: Mood Disorder Questionnaire.
b European version of the Addiction Severity Index, score 0–9.f the study.
Mean age of all 375 eligible patients was 40.4 years (SD ± 11.0)
with MDQ  negatives being somewhat older than MDQ  positives
(41.9 versus 38.4 years, p = .002). The majority (74%) of the patients
were males with signiﬁcantly more males among the MDQ  pos-
itives (83%) compared to the MDQ  negatives (70%) (p = .005).
There were no signiﬁcant differences regarding education level,
employment status and EuropASI severity scores regarding medical
condition, alcohol, family and social relations and mental problems.
However, there was a signiﬁcant difference on the EuropASI sever-
ity rating drugs (p = .000) between the MDQ  positive and negative
patients (Table 1).
Patients with an assessment at T1 (N = 170, 45%) did not differ
signiﬁcantly from patients without an assessment (N = 205, 55%) in
terms of age, gender, and employment status. However, MDQ  pos-
itives at T0 with an assessment at T1 (N = 111) were less educated
than those without an assessment (N = 50). Moreover, MDQ  neg-
atives at T0 with an assessment at T1 had a higher mean section
A score (0–13) than MDQ  negatives without an assessment (8.87;
SD ± 2.63 versus 5.42; SD ± 3.25, p < .01). The severity of alcohol or
Q  negatives N = 214 (57%) Total sample N = 375 P
.93 (11.56) 40.43 (10.97) .002
 (70%) 300 (74%) .005
 (30%) 103 (26%)
 (66%) 274 (68%) .337
 (21%) 79 (20%)
 (13%) 50 (12%)
.192
 (18%) 151 (38%)
 (41%) 179 (44%)
 (41%) 73 (18%)
.13 (2.02) 2.21 (1.94) .415
.24 (2.40) 4.09 (2.44) .183
.37 (2.61) 2.94 (2.75) .000
.10 (1.64) 3.30 (1.96) .028
.09 (1.86) 4.32 (1.99) .055
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Table 2
Bipolar diagnosis (BD) according to SCID results at T1a versus MDQ score at T0.b
SCID Total
BD positive BD negative
MDQ
Positive 23 88 111
Negative 12 47 59
Total 35 135 170
d
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3.4. BD symptom related disorders
T
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da Assessment at follow-up.
b Assessment at baseline.
rug use (ASI score) did not differ between these groups (data not
hown).
.2. Prevalence of mood and substance related disorders
Of the 170 patients with a SCID at T1, 35 patients (20.6%)
et  criteria for a lifetime diagnosis of BD (BD-I N = 8, BD-II
 = 25 and BD-NOS, N = 2), 72 patients (42.4%) had a lifetime
ajor depressive disorder, 10 patients (5.9%) a lifetime depressive
isorder NOS, 10 patients (5.9%) met  criteria for a substance-
nduced mood disorder with depressed features, 1 patient (0.6%)
ad a substance-induced mood disorder with manic features, and
 patient (0.6%) a mood disorder due to a somatic condition.
orty-one patients (24.1%) did not meet criteria for any mood
isorder.
Fifty-eight (34.1%) patients had one lifetime SUD diagnosis, 108
atients (63.5%) had two or more SUD diagnoses, and 4 patients
2.4%) had no lifetime SUD at all. Fifty-nine patients (34.7%) had a
urrent diagnosis of AUD, 31 patients (18.2%) of cocaine or stim-
lant dependence, 26 patients (15.2%) of cannabis dependence,
 patients (4.7%) of opiate dependence, and 5 patients (2.9%)
f benzodiazepine dependence. Forty-one (24.1%) patients were
able 3
eighted sensitivity, speciﬁcity, false positives, false negatives, positive predictive value
ikelihood ratio (LR−) of the MDQ  at T0 (N = 170).
MDQ  classic (95%CI) MDQ  classic + D + E (9
Sensitivity .43 (.32–.54) .21 (.10–.32) 
Speciﬁcity .57 (.50–.64) .82 (.77–.87) 
False  positives .43 .18 
False  negatives .57 .79 
PPV .21 (.13–.29) .23 (.11–.35) 
NPV  .80 (.75–.95) .65 (.59–.71) 
LR+  1.00 1.17 
LR-  1.00 .96 
able 4
revalence and operating characteristics of the MDQ  of 159 patients for borderline 
eﬁcit/hyperactivity disorder (ADHD) at T1.
BDa BPD 
Prevalence, n (%) 31 (19.5) 23 (14.5) 
Sensitivity, (95% CI) .45 (.32–.48) .30 (.16–.44) 
Speciﬁcity, (95% CI) .54 (.47–.61) .77 (.70–.84) 
False  positives .46 .23 
False  negatives .55 .70 
PPVb, (95% CI) .20 (.13–.27) .11 (.05–.17) 
NPVc, (95% CI) .79 (.72–.86) .79 (.72–.86) 
AUCd, (95% CI) .51 (.41–.61) .61 (.50–.73) 
LR+e .98 1.30 
LR−f 1.02 .91 
a Different operating characteristics of BD compared to Table 3 due to a different numb
b Positive predictive value.
c Negative predictive value.
d Area under the curve.
e Positive likelihood ratio.
f Negative likelihood ratio.ependence 124 (2012) 235– 241
problems users of alcohol and/or drugs but did not meet criteria
of any current SUD.
3.3. Validity of the MDQ
Table 2 shows that 23 of the 35 patients (65.7%) with BD had
a positive MDQ  score and 47 of the 135 patients (34.8%) without
BD had a negative MDQ  score resulting in a weighted sensitivity
of .43 and a weighted speciﬁcity of .57, a weighted LR+ of 1.00,
a weighted LR− of 1.00, a PPV of .21, and a NPV of .80 (Table 3).
As expected based on the LR+ and the LR−, the area under the
curve (AUC) was  .50 (95% CI .41–.61). Omission of the impairment
criterion (section C), increases the number of patients with a
positive MDQ  score (N = 111) and BD from 23 to 32 and decreases
the number of patients with a negative MDQ  score (N = 59) and BD
from 12 to 3, resulting in increased sensitivity of .85 at the expense
of a decreased speciﬁcity of .24, a better LR+ of 1.12 and a better
LR− of .63, a PPV of .23 and a NPV of .86.
Table 3 also shows that introduction of the D and E criteria
results in an expected increase in speciﬁcity (.82) at the expense
of a decrease in sensitivity (.21). Also restricting BD symptoms
to substance free periods (criteria D and E) and removing func-
tional impairment (criterion C: allowing BD I to be included as
a case) did not improve the sensitivity and speciﬁcity of the
MDQ  to detect BD (Table 3, last column). The positive and neg-
ative likelihood ratios (LR+, LR−) ranged from 1–1.42 to 1–.63,
respectively.
Validity indicators based on the MDQ  assessment at T1 were
very similar and certainly not better than those based on the MDQ
assessment at baseline (T0) (data not shown).Of the 170 patients with a SCID at T1, 159 (94%) also completed
all the other diagnostic instruments (DIS, SIDP-IV) at T1. Of the 31
 (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative
5%CI) MDQ  A + B (95%CI) MDQ  A + B + D + E (95%CI)
.85 (.76–.94) .44 (.31–.57)
.24 (.18–.30) .69 (.63–.75)
.76 .31
.15 .56
.23 (.17–.29) .27 (.18–.36)
.86 (.77–.95) .83 (.77–.89)
1.12 1.42
.63 .81
personality disorder (BPD), antisocial personality disorder (APD) and attention
APD ADHD Any externalizing disorder
31 (19.5) 48 (30.2) 98 (38)
1.00 .57 (.45–.69) .59 (.49–.69)
.61 (55–.67) .60 (.53–.67) .67 (.60–.74)
.39 .40 .33
0 .43 .41
.30 (.21–.39) .35 (.26–.44) .52 (.43–.61)
1.00 .79 (.72–.86) .73 (.66–.80)
.55 (.44–.66) .63 (.54–.72) .60 (.51–.68)
2.56 1.43 1.79
0 .72 .61
er of patients (159 versus 170).
ohol D
p
1
B
p
p
C
i
c
i
A
a
T
d
A
o
M
T
w
.
t
4
p
t
b
B
o
t
p
A
n
p
M
a
1
t
b
p
p
B
t
v
n
c
p
t
i
q
ﬁ
c
s
c
t
d
A
S
t
c
ﬁJ. van Zaane et al. / Drug and Alc
atients (19.5%) with BD, 8 (25%) also had BPD, 2 (6.4%) APD and
0 (32.2%) ADHD. Of the 128 patients without BD, 15 (11.7%) had
PD, 29 (22.7%) APS, and 38 (29.7%) ADHD. The relative risks of the
resence of BPD, APD and ADHD in patients with BD compared to
atients without BD were 2.2 (95% CI 1.03–4.72) for BPD, 0.28 (95%
I 0.07–1.13) for APD, and 1.09 (95% CI 0.61–1.93) for ADHD, mean-
ng that BD relatively often co-occurred with BPD, the BD tended to
o-occur less often with APD and that ADHD was  equally present
n patient with and without BD.
The standard MDQ  operating characteristics with BD, BPD, APD,
DHD and any externalizing disorder (BD and/or BPD and/or APD
nd/or ADHD) as external criterion for this population are shown in
able 4. In order to compare the performance of the MDQ  for these
ifferent external criteria, we calculated areas under the curve. The
UCs ranged from .51 (BD) to .63 (ADHD). The 95% CI of the AUCs
f BD, BPD and APD all included 0.50, indicating that the standard
DQ  performed not better than chance for these three disorders.
he performance to detect ADHD and any externalizing disorder
as slightly better with AUCs of .63 (95%CI .54–.72) and .60 (95%CI
51–.68) respectively, but 95% CI’s largely overlapped with those of
he AUC of the other external criteria (BD, BPD and APD).
. Discussion
The primary objective of this study was to evaluate the screening
roperties of the MDQ  to detect BD in a treatment seeking popula-
ion of patients with SUD. Our ﬁrst hypothesis that the MDQ  would
e a valid screen due to an expected relatively high prevalence of
D in this population was not conﬁrmed. With the SCID diagnosis
f BD-I, DB-II or BD-NOS as “golden standard” (prevalence 21%),
he performance of the MDQ  in this population was  very disap-
ointing: sensitivity = .43, speciﬁcity = .57, PPV = .21, NPV = .80, and
UC = .50. These data show that the PPV and the NPV of the origi-
al MDQ  (A + B + C) in this population are (almost) the same as the
revalence and 1-prevalence, indicating that knowledge from the
DQ  did not improve the prediction of the presence or absence of
 BD at all (which is also indicated by the AUC of 0.50, the LR+ of
.00 and the LR− of 1.00, i.e., validity indicators that are not better
han estimates based on prevalence information only). It should
e noted that a relatively high prevalence of a condition in a sam-
le results in increased values of positive and negative predictive
ower (Baldesarini et al., 1983). In our sample the prevalence of
D according to the SCID diagnosis was 35% (59/170, Table 2) and
his resulted in overly optimistic negative and positive predictive
alues.
Due to the small number of patients in some of the diag-
ostics groups it was not possible to investigate whether these
haracteristics were better for patients with a BD-I diagnosis com-
ared to patients with a BD-II diagnosis. However, omission of
he impairment criterion (section C) did not result in a substantial
mprovement of the screening capacity of the MDQ.
Furthermore, our second hypothesis that addition of two extra
uestions (sections D and E) to the MDQ  would improve the speci-
city without (seriously) lowering the sensitivity was only partly
onﬁrmed. In fact, speciﬁcity increased from .57 to .82, while sen-
itivity decreased from .43 to .21. The latter (sensitivity of .21) is of
ourse unacceptable for an instrument that aims to detect poten-
ial cases of BD in patients seeking treatment for a substance use
isorder.
Our third hypothesis that the high prevalence of BPD (14.5%),
PD (19.5%) and ADHD (30.2%) in our treatment seeking AUD and
UD patients would result in a high rate of false positives (FPs) and
hus in low speciﬁcity was conﬁrmed (Table 4). The FP rate of the
lassic MDQ  was indeed rather high (46%) resulting in low speci-
city (.54). This is consistent with the ﬁndings of Zimmerman et al.ependence 124 (2012) 235– 241 239
(2010) who showed in their study of 534 psychiatric outpatients
that BPD was 4 times more frequently diagnosed in the MDQ  pos-
itive group than in the MDQ  negative group, indicating that the
MDQ  can also detect externalizing disorders other than BD. We
therefore hypothesized that the MDQ  would be able to perform
best in the detection of any externalizing disorder rather than BD
alone. However, broadening the external criterion to any external-
izing disorders did not really improve the performance of the MDQ
in this population (AUC = .60, 95%CI .51–.68).
What can we conclude? First, based on our ﬁndings, we  can-
not recommend the original nor any of the adapted versions of
the MDQ  as a useful screening instrument to detect the presence
(or absence) of BD in a population of treatment seeking patients
with SUD. We  even cannot recommend the MDQ  in this popula-
tion as a screener for the presence or absence of any externalizing
disorder. Still, it is very important that BD is detected early in
patients with SUD. According to Benazzi and Akiskal (2003),  the
most important clinical symptoms of patients with BD-II, the type
of BD that is hard to detect, are energized activity and irritable
mood associated with racing thoughts, but these symptoms are also
very common among almost all cocaine and amphetamine users,
even among those without BD. When we  obtained our disappoint-
ing/unexpected ﬁndings, we  thought it all over again. Based on our
clinical experience/impression, we  then thought the key questions
that every patient who seeks help in an addiction center should be
asked, would be if (s) he had ever had an episode without using alco-
hol or drugs that was characterized by (1) lack of need to sleep, (2)
energized activity and/or (3) irritable mood associated with racing
thoughts. However, a post hoc analysis of our data based on these
three questions (+ section B and C) did not substantially improve
the performance of the MDQ. Thus, the problem of how to detect BD
in an addiction population remains unsolved. On the other hand,
with a NPV of .80 one could argue that the MDQ is a reasonable good
tool to rule out BD in addiction settings where a psychiatric inter-
view is not standard at intake: only those who screen positive need
to have a proper diagnostic assessment, essentially decreasing the
burden of psychiatric interview for BD at intake.
The current study has both strengths and limitations. The
strengths of our study are the relatively large sample size in a dif-
ﬁcult, but very relevant, population when compared to previous
studies (see also Chung et al., 2008, p. 465), and the diagnoses
of BPD, APD and ADHD diagnoses that were based on structured
assessments by specially trained interviewers. Nevertheless, the
sample size is also small, as indicated by the relatively broad 95%
conﬁdence intervals. However, the general picture is still very clear
and the limited sample size is not a serious problem for the inter-
pretation of our ﬁndings. The ﬁrst limitation is the relatively short
detoxiﬁcation period. However, this limitation can also be seen as
a strength of the study, because clinicians like to do the screen-
ing as soon as possible after intake. The second limitation is more
important. This limitation relates to the fact that the MDQ  negatives
with a SCID were not fully representative for all MDQ  negatives in
terms of their MDQ  score. MDQ  negatives with a SCID had a sig-
niﬁcantly and substantially higher mean MDQ  section A score at
T0 than MDQ  negatives without a SCID (d = 1.17; p < .01). This may
have caused an underestimation of the validity of the MDQ  due to
a biased increase in the number of false positives. In order to esti-
mate the possible effect of this unexpected design weakness, we
performed a post hoc sensitivity analysis in which we  moved 6–8
of the 12 false negative patients (Table 2) to the true positive cat-
egory. However, this procedure failed to substantially improve the
overall performance of the MDQ  to detect BD in a treatment seeking
population of SUD patients. Another limitation is that the reliabil-
ity of the diagnostic evaluation was not formally tested. This could
also have led to a poor performance of the screener. Stewart and El-
Mallakh (2007) and Goldberg et al. (2008) reported overdiagnosis
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f BD in patients with active SUD when diagnosed by psychiatrists.
owever, it seems unlikely that we overdiagnosed BD in our study
opulation given the PPV of only .20 and a false positive rate of .46
Table 4). Finally, one could argue that many of the patients in the
non-bipolar” group may  in fact have a softer version of BD that was
ot identiﬁed by the SCID. However, we explicitly looked for sub-
hreshold cases and included bipolar NOS in the group of patients
ith a bipolar disorder.
. Conclusions
The MDQ  is not a suitable screening instrument for the detection
f BD or other externalizing disorders, but it could be used to rule
ut the presence of BD in treatment seeking substance use disorder
atients.
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